Clinical Trial: Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy V

Brief Summary: The purpose of this study is to investigate the effect of AZD3161 on mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin.

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: Results of mechanical pain testing using Quantitative Sensory Testing [ Time Frame: Day 1 ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Number of participants with Adverse Events [ Time Frame: Range of 14 days ]
  • Vital signs [ Time Frame: Day 1 ]
    (blood pressure, heart rate, pulse)
  • Clinical chemistry (urinalysis, hematology) [ Time Frame: At follow up (a range of 8-15 days after Day 1) ]
  • The effect of AZD3161 on axon reflex flare in normal and UVC irradiated skin using a Laser doppler scan [ Time Frame: Day 1 ]


Original Secondary Outcome: Same as current

Information By: AstraZeneca

Dates:
Date Received: November 10, 2010
Date Started: December 2010
Date Completion:
Last Updated: April 11, 2011
Last Verified: April 2011